OKYO Pharma (NASDAQ:OKYO) Earns Buy Rating from HC Wainwright

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $7.00 target price on the stock.

OKYO Pharma Stock Up 1.3 %

NASDAQ:OKYO traded up $0.02 on Monday, reaching $1.14. 24,936 shares of the company’s stock were exchanged, compared to its average volume of 251,364. The business has a fifty day moving average of $1.08 and a 200-day moving average of $1.07. OKYO Pharma has a 52-week low of $0.81 and a 52-week high of $1.90.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.